AgomAb Therapeutics N.V. American Depositary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGMB research report →
Range $35 – $35
Price Chart
About the company
AgomAb Therapeutics N. V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies.
- CEO
- Tim Knotnerus
- IPO
- 2026
- Employees
- 62
- HQ
- Antwerp, VL, BE
Get TickerSpark's AI analysis on AGMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $268.40M
- P/E
- -6.29
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 0.91
- EV/EBITDA
- -0.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -19.70%
- ROIC
- -11.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-59,275,000
- Net Income
- $-62,547,000-35.2%
- EPS
- $-1.28-1.6%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $17.82
- 52W Low
- $5.39
- 50D MA
- $8.70
- 200D MA
- $11.69
- Beta
- 1.80
- RSI (14)
- 23
- Avg Volume
- 208.99K
No earnings-call transcripts are available for AGMB yet.
- Free Float
- 74.0%
- Shares Outstanding
- 49.25M
- Float Shares
- 36.45M
of shares held by institutions
34 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eqt Fund Management S.A R.L. | 5.14M | 0 |
| Sanofi | 2.78M | 0 |
| Cormorant Asset Management, LP | 2.47M | 0 |
| Pfizer Inc | 2.15M | ▲ 2.08M |
| Tcg Crossover Management, LLC | 1.82M | ▼ 232.40K |
| Nantahala Capital Management, LLC | 1.75M | ▲ 179.58K |
| Redmile Group, LLC | 1.74M | ▼ 993.70K |
| Federated Hermes, Inc. | 1.61M | ▼ 3.99K |
| Casdin Capital, LLC | 1.55M | 0 |
| Fmr LLC | 1.46M | 0 |
| Aberdeen Group PLC | 1.24M | ▲ 390.71K |
| Perceptive Advisors LLC | 600.00K | 0 |
Held by 7 ETFs
Biggest fund positions in AGMB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Epstein David R | buy | 5,000 |
| Nov 13, 26 | Epstein David R | buy | 4,960 |
| Nov 13, 26 | Epstein David R | buy | 5,000 |
| Nov 13, 26 | Epstein David R | buy | 20 |
| Nov 13, 26 | Epstein David R | buy | 5,000 |
| Nov 5, 26 | Epstein David R | buy | 5,000 |
| Nov 5, 26 | Epstein David R | buy | 5,000 |
| Nov 5, 26 | Epstein David R | buy | 5,000 |
| Oct 21, 26 | Epstein David R | buy | 5,000 |
| Oct 21, 26 | Epstein David R | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AGMB coverage
Recent articles, reports, and earnings notes.
No research on AGMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGMB report →Agomab to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 4
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
globenewswire.com · Oct 13
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
seekingalpha.com · Oct 1
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
benzinga.com · Oct 1
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
globenewswire.com · Oct 1
AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50
defenseworld.net · Sep 30
AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
seekingalpha.com · Sep 16
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
globenewswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.